Expression of CIITA-related MHCII molecules in tumors linked to prognosis in hepatocellular carcinoma

International Journal of Oncology

Volumn 34, Issue 3, 2009, Pages 681-688

  Xie, Xing Wang ^a   Mei, Ming Hui ^b   Liao, Wei Jia ^b   Qian, Li Hua ^a   Yu, Xin ^a   Fei, Ran ^a   Qin, Li Ling ^b   Zhang, Heng Hui ^a   Peng, Ji Run ^a   Shen, Dan Hua ^a   Wei, Lai ^a   Chen, Hong Song ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b GUILIN MEDICAL UNIVERSITY   (China)

Author keywords

CIITA; Gene expression profile; Hepatocellular carcinoma; MHC II genes; Microarray; Recurrence

Indexed keywords

CD45 ANTIGEN; CD68 ANTIGEN; HLA ANTIGEN CLASS 2 TRANSACTIVATOR PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE LOCATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL TIME; UPREGULATION; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CLUSTER ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENES, MHC CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 64549162045     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000194     Document Type: Article

References (27)

1. Tang ZY, Ye SL, Liu YK, et al: A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 187-196, 2004.
2. Lee JS and Thorgeirsson SS: Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction and identification of therapeutic targets. Gastroenterology 127: 51-55, 2004.
3. Lee JS, Chu IS, Heo J, et al: Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40: 667-676, 2004.
4. Ye QH, Qin LX, Forgues M, et al: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9: 416-423, 2003.
5. Iizuka N, Oka M, Yamada-Okabe H, et al: Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 361: 923-929, 2003.
6. Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, et al: Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol 24: 1140-1150, 2006.
7. Tusher VG, Tibshirani R and Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121, 2001.
8. Dennis G Jr, Sherman BT, Hosack DA, et al: DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 4: P3, 2003.
9. Ho MC, Lin JJ, Chen CN, et al: A gene expression profile for vascular invasion can predict the recurrence after resection of hepatocellular carcinoma: a microarray approach. Ann Surg Oncol 13: 1474-1484, 2006.
10. Budhu A, Forgues M, Ye QH, et al: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10: 99-111, 2006.
11. Iizuka N, Oka M, Yamada-Okabe H, et al: Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 62: 3939-3944, 2002.
12. Kurokawa Y, Matoba R, Takemasa I, et al: Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol 41: 284-291, 2004.
13. Ohira M, Ohdan H, Mitsuta H, et al: Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation 82: 1712-1719, 2006.
14. Takayama T, Sekine T, Makuuchi M, et al: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356: 802-807, 2000.
15. Shirabe K, Matsumata T, Maeda T, Sadanaga N, Kuwano H and Sugimachi K: A long-term surviving patient with hepatocellular carcinoma including lymphocytes infiltration: a clinicopathological study. Hepatogastroenterology 42: 996-1001, 1995.
16. Schoniger-Hekele M, Hanel S, Wrba F and Muller C: Hepatocellular carcinoma - survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int 25: 62-69, 2005.
17. Reinisch W, Holub M, Katz A, et al: Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma. J Immunother 25: 489-499, 2002.
18. Matoba K, Iizuka N, Gondo T, et al: Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int J Cancer 115: 231-240, 2005.
19. Wright KL and Ting JP: Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 27: 405-412, 2006.
20. Holling TM, van EM, Jager MJ and van EP: Epigenetic silencing of MHC2TA transcription in cancer. Biochem Pharmacol 72: 1570-1576, 2006.
21. Shi B, Vinyals A, Alia P, et al: Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription implication of CIITA in tumor and metastasis development. Int J Biochem Cell Biol 38: 544-562, 2006.
22. Morimoto Y, Toyota M, Satoh A, et al: Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells. Br J Cancer 90: 844-852, 2004.
23. Hippo Y, Yashiro M, Ishii M, et al: Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res 61: 889-895, 2001.
24. Boye K, Andersen K, Tveito S, Oyjord T and Maelandsmo GM: Interferon-gamma-induced suppression of S100A4 transcription is mediated by the class II transactivator. Tumour Biol 28: 27-35, 2007.
25. Van SN, Quinten E, Alblas G, et al: Constitutive and IFN gamma-induced activation of MHC2TA promoter type III in human melanoma cell lines is governed by separate regulatory elements within the PIII upstream regulatory region. Mol Immunol 44: 2036-2046, 2007.
26. Satoh A, Toyota M, Ikeda H, et al: Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 23: 8876-8886, 2004.
27. Iizuka N and Oka M: CIITA methylation and decreased levels of HLA-DR in tumour progression. Br J Cancer 91: 813814-813815, 2004.